Risk factor
Negligible price volatility
Profitability factor
Very strong margins and returns
About
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Target Price
The average target price of CIPLA.NS is 1664 and suggests 25% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
Buy
Sell